SRRK Strangle Strategy
SRRK (Scholar Rock Holding Corporation), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SRRK (Scholar Rock Holding Corporation) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $6.01B, a beta of 0.71 versus the broader market, a 52-week range of 27.07-51.625, average daily share volume of 1.5M, a public-listing history dating back to 2018, approximately 128 full-time employees. These structural characteristics shape how SRRK stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.71 places SRRK roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on SRRK?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current SRRK snapshot
As of May 15, 2026, spot at $49.16, ATM IV 51.90%, IV rank 11.33%, expected move 14.88%. The strangle on SRRK below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on SRRK specifically: SRRK IV at 51.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a SRRK strangle, with a market-implied 1-standard-deviation move of approximately 14.88% (roughly $7.31 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SRRK expiries trade a higher absolute premium for lower per-day decay. Position sizing on SRRK should anchor to the underlying notional of $49.16 per share and to the trader's directional view on SRRK stock.
SRRK strangle setup
The SRRK strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SRRK near $49.16, the first option leg uses a $51.62 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SRRK chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SRRK shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $51.62 | N/A |
| Buy 1 | Put | $46.70 | N/A |
SRRK strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
SRRK strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on SRRK. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on SRRK
Strangles on SRRK are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SRRK chain.
SRRK thesis for this strangle
The market-implied 1-standard-deviation range for SRRK extends from approximately $41.85 on the downside to $56.47 on the upside. A SRRK long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SRRK IV rank near 11.33% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on SRRK at 51.90%. As a Healthcare name, SRRK options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SRRK-specific events.
SRRK strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SRRK positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SRRK alongside the broader basket even when SRRK-specific fundamentals are unchanged. Always rebuild the position from current SRRK chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on SRRK?
- A strangle on SRRK is the strangle strategy applied to SRRK (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SRRK stock trading near $49.16, the strikes shown on this page are snapped to the nearest listed SRRK chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SRRK strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SRRK strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 51.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SRRK strangle?
- The breakeven for the SRRK strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SRRK market-implied 1-standard-deviation expected move is approximately 14.88%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on SRRK?
- Strangles on SRRK are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SRRK chain.
- How does current SRRK implied volatility affect this strangle?
- SRRK ATM IV is at 51.90% with IV rank near 11.33%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.